Understanding how CEACAM1 affects B-cell signaling and treatment in mantle cell lymphoma
Official title: The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
Funded at Beckman Research Institute/city of Hope · NIH-10880440 · Data updated 2026-11-12
This study is looking at a protein called CEACAM1 that might affect how certain immune cells work in people with mantle cell lymphoma, especially those who aren't responding well to treatments like ibrutinib, to find new ways to help improve their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $381,482 |
| NIH project number | 5R01CA262754-04 |
| Project ID | NIH-10880440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with mantle cell lymphoma, particularly those who have not responded to standard treatments.
✕Less likely to help
Patients with other types of non-Hodgkin lymphoma or those who do not have mantle cell lymphoma may not benefit from this research.
What this research studies
This research investigates the role of CEACAM1, a protein found on the surface of certain immune cells, in the signaling pathways of B-cells that contribute to mantle cell lymphoma (MCL). By using advanced techniques like CRISPR-Cas9 and gene expression profiling, the study aims to uncover how CEACAM1 influences the effectiveness of current treatments, particularly in patients who do not respond to standard therapies like ibrutinib. The goal is to identify new therapeutic targets that could improve outcomes for MCL patients. Patients may benefit from insights that could lead to more effective treatment strategies tailored to their specific cancer biology.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with mantle cell lymphoma.
How similar studies have gone: Previous research has shown promising results in targeting B-cell receptor signaling in other B-cell malignancies, suggesting potential for success in this area as well.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Ngo, Vu Nguyen — Beckman Research Institute/city of Hope
- Study coordinator: Ngo, Vu Nguyen
Related research
Other NIH-funded projects on the same topics.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Targeting MALT1 to Strengthen Anti-Lymphoma Immunity and Boost Immunotherapy
Aims to improve treatment for a common type of B-cell lymphoma by blocking a specific protein (MALT1) to enhance the body's immune attack and response to existing therapies.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.